Edwards Lifesciences Corp
NYSE:EW

Watchlist Manager
Edwards Lifesciences Corp Logo
Edwards Lifesciences Corp
NYSE:EW
Watchlist
Price: 70.48 USD 0.14% Market Closed
Market Cap: 41.6B USD
Have any thoughts about
Edwards Lifesciences Corp?
Write Note

Edwards Lifesciences Corp
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Edwards Lifesciences Corp
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Edwards Lifesciences Corp
NYSE:EW
Total Equity
$9.5B
CAGR 3-Years
20%
CAGR 5-Years
20%
CAGR 10-Years
17%
Becton Dickinson and Co
NYSE:BDX
Total Equity
$25.9B
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
18%
Boston Scientific Corp
NYSE:BSX
Total Equity
$20.7B
CAGR 3-Years
8%
CAGR 5-Years
16%
CAGR 10-Years
12%
Stryker Corp
NYSE:SYK
Total Equity
$20.1B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
9%
Abbott Laboratories
NYSE:ABT
Total Equity
$39.3B
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
6%
Intuitive Surgical Inc
NASDAQ:ISRG
Total Equity
$15.6B
CAGR 3-Years
11%
CAGR 5-Years
15%
CAGR 10-Years
18%
No Stocks Found

Edwards Lifesciences Corp
Glance View

Market Cap
41.6B USD
Industry
Health Care

Edwards Lifesciences Corp., a leader in heart valve technologies and hemodynamic monitoring, has carved out a vital niche in the medical device industry. Founded in 1958 and based in Irvine, California, the company has consistently focused on innovative solutions to treat advanced cardiovascular diseases. Its flagship product, the transcatheter aortic valve replacement (TAVR), revolutionized how patients with severe aortic stenosis are treated, allowing doctors to perform minimally invasive procedures that significantly improve patient outcomes. As the global population ages and cardiovascular diseases become increasingly prevalent, Edwards is well-positioned to capitalize on this growing demand, with a robust pipeline of products aimed at addressing unmet medical needs. For investors, Edwards Lifesciences represents a compelling opportunity to tap into the expanding medical technology market. The company's strong financial performance, characterized by consistent revenue growth and impressive profit margins, highlights its effective execution and market leadership. Moreover, Edwards is committed to innovation, investing heavily in research and development, which not only fuels new product launches but also enhances its competitive edge. With a focus on long-term growth, expanding market presence, and a dedication to improving patient care, Edwards Lifesciences stands out as a promising investment for those looking to gain exposure to the dynamic healthcare sector.

EW Intrinsic Value
54.97 USD
Overvaluation 22%
Intrinsic Value
Price

See Also

What is Edwards Lifesciences Corp's Total Equity?
Total Equity
9.5B USD

Based on the financial report for Sep 30, 2024, Edwards Lifesciences Corp's Total Equity amounts to 9.5B USD.

What is Edwards Lifesciences Corp's Total Equity growth rate?
Total Equity CAGR 10Y
17%

Over the last year, the Total Equity growth was 43%. The average annual Total Equity growth rates for Edwards Lifesciences Corp have been 20% over the past three years , 20% over the past five years , and 17% over the past ten years .

Back to Top